In short. The risks of chasing an undefined target, and the alternatives of doing less, doing one thing, or doing nothing while deciding.
Key points
- A small first step in a reversible substance is a better proposition than a large one, on both the risk side and the reversibility side.
- It is not a risk-free proposition, and treating it as one because the intention was modest is how the risks of a plan stop being discussed.
The risks in this category divide into the ones that belong to the substances and the one that belongs to the objective, and the second is the one that gets left out.
The risk of an unmeasurable target
A person pursuing a natural result is pursuing a judgement made by other people and by themselves, and there is no point at which the goal can be confirmed as reached. That is how a conservative plan becomes a sequence of additions: each one is justified by the same objective, no single addition is large, and the stopping point has to be supplied by the person rather than by the plan. The characteristic failure of this category is not a single over-treatment but an accumulation that nobody decided on.
The clinical risks, reduced and not removed
Bruising and swelling are near-universal and settle. Nodules and lumps can form and may need treatment. Asymmetry can result and may be more noticeable than the asymmetry being corrected. Infection can follow any injection. Vascular occlusion is rare and serious, and it can cause skin loss or, in the worst case, visual loss. A conservative plan reduces exposure, because fewer injections and smaller volumes mean fewer opportunities for each risk. It does not remove the labelled risks of injecting anything, and the intention behind the plan does not change what the labelling says.
Restraint lowers risk without removing it
A small first step in a reversible substance is a better proposition than a large one, on both the risk side and the reversibility side. It is not a risk-free proposition, and treating it as one because the intention was modest is how the risks of a plan stop being discussed.
The alternatives
Doing one thing is the practical alternative within treatment: a single area, a reversible substance, a modest amount, a review at a defined point. It produces information as well as a change, and it keeps every later decision open. Waiting is the alternative outside treatment, and it is more useful than it sounds, because a finding that has appeared recently may be swelling or a temporary change and a photograph taken now compared with one in six months answers a question no single visit can. Doing nothing at all is a reasonable position where no specific finding can be named, because a plan organised around an unmeasurable objective has no endpoint and not starting keeps every option available.
Signs to have assessed urgently rather than watched
- Severe pain, or skin that becomes dusky, mottled or pale after an injection.
- A change in vision, or pain around the eye, after any injection to the face.
- A fever with spreading redness, or a lump that is painful and enlarging.
Those are medical emergencies rather than treatment side effects, and they need immediate assessment rather than a page about results.
Frequently asked questions
What is the main risk of pursuing a natural result?
That the target cannot be measured, so there is no point at which it is reached. A conservative plan can become a series of additions, each justified by the same unmeasurable objective, until the result is further from natural than anything that would have been chosen at the start. That is the characteristic failure of this category.
Are the clinical risks lower if the plan is conservative?
Lower and not absent. Fewer injections and smaller volumes mean fewer opportunities for bruising, nodules, asymmetry, infection and vascular occlusion. The labelled risks of injecting anything remain, and a conservative plan reduces what is exposed rather than removing the risk.
What is the alternative to adding more?
Waiting and reviewing. A defined review point exists so that the decision to add anything can be made with information rather than in advance. Many people find that the conservative first step is enough, and the review is what makes that discoverable rather than assumed.
Risks & Limitations
- No validated measure of a natural appearance exists, so a claim that a result will look natural cannot be tested at all.
- No regulator approves an appearance; approval belongs to the substance, the device and the indication behind it.
- A result that reads as natural is still a result produced by treatment, and it carries the same labelled risks.
- Reversibility is real for a substance and partial for an outcome: dissolving a filler is not the same as undoing a result.
- The characteristic failure of this category is accumulation, because an unmeasurable target has no natural stopping point.
When to Seek Care
- Severe pain, or skin that becomes dusky, mottled or pale after an injection — seek emergency care immediately.
- A change in vision, or pain around the eye, after any injection to the face — seek emergency care immediately.
- A fever with spreading redness, or a lump that is painful and enlarging, is assessed by a clinician rather than watched.
- A result that is uneven, or tissue that does not settle after a filler has been dissolved, is assessed by a clinician rather than treated further.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — approved dermal fillers and their labelled indications
- National Medical Products Administration (NMPA, China) — approved products and their indications
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews of dermal fillers and facial volumising
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is a review of published evidence and regulation, not medical advice, and it does not cite individual studies. It is not a booking page, it does not recommend a treatment, and it does not promise any appearance. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.